Shaheen touts diabetes groups' backing for her bill to cap insulin costs at $35
The New Hampshire Democrat's office circulated statements from five diabetes and health organizations urging Congress to pass the INSULIN Act, which would limit monthly out-of-pocket insulin costs for insured patients.
U.S. Sen. Jeanne Shaheen, D-N.H., on Friday circulated statements from diabetes advocacy and medical groups urging Congress to pass her bill to cap monthly out-of-pocket insulin costs at $35 for Americans with insurance.
Shaheen's office said the legislation, the Improving Needed Safeguards for Users of Lifesaving Insulin Now Act, or INSULIN Act, has "robust bipartisan support" in the House and Senate and is "closer than ever before" to passing the Senate. According to the office, the bill advanced out of the Senate Health, Education, Labor and Pensions Committee in July, and companion legislation was introduced in the House in September.
The statements came from Breakthrough T1D, the American Diabetes Association, the Diabetes Leadership Council, the Endocrine Society and the National Kidney Foundation.
Lisa Murdock, the American Diabetes Association's chief advocacy officer, cited the group's survey finding that the cost of insulin has led 41 percent of households to skip or ration doses. She said the bill "would make insulin affordable for the 2.2 million Americans enrolled in federally regulated commercial plans outside state jurisdiction."
Nancy D'Hondt, board chair of the Diabetes Leadership Council and a clinical pharmacist, said people with commercial insurance "are not protected in the same way that Medicare beneficiaries are."
Jesse Roach of the National Kidney Foundation said diabetes accounts for half of all new cases of kidney failure.
Shaheen's office said more than 40 million Americans live with diabetes. It also cited American Diabetes Association polling that found 40 percent of respondents who rely on insulin report paying more than $150 a month for it, and 76 percent of respondents across political parties support a $35 limit on cost sharing.
Shaheen is co-chair of the Senate Diabetes Caucus. Her office said she has pressed to hold insulin manufacturers, insurers and pharmacy benefit managers accountable for what it called the "skyrocketing cost" of insulin. The release included no response from those industries.
This brief was drafted by AI from a public agency or political press release and published by The New England Signal. Why we use AI for stories like this one.